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1. Introduction
Several neurological manifestations in association with the corona
virus disease 2019 (COVID-19) [1,2] have been reported. Cases of
post-infectious transverse myelitis (TM) and para-infectious TM associ
ated with COVID-19 have been published, and longitudinally extensive
[3,4], acute necrotizing [5], and multifocal TM cases have also been
reported [6]. Other viral pathogens that can be causative of TM include
herpes simplex, Epstein-Barr, varicella-zoster, cytomegalovirus, hepa
titis B, Zika, dengue, and chikungunya viruses [7]. Flaviviruses (yellow
fever, tick-borne encephalitis, Japanese encephalitis, West Nile, dengue,
and Zika viruses) and coronaviruses (Middle East respiratory syndrome,
SARS-CoV-1, and SARS-CoV-2 viruses) are RNA based respiratory vi
ruses with neurotropic properties that allow them to bypass or alter the
immune mechanisms, which can lead to viral-induced neurological
manifestations. [8] The host-virus interaction triggers the immune
mechanisms, and genetics may play an important role too. Therefore, it
is interesting that only some individuals develop neurological manifes
tations after infection with potentially neurotropic pathogens.
Here, we report a case of late-onset rapidly progressive MRInegative-myelitis after COVID-19 infection. This case is compelling, as
the patient presented with myelopathic symptoms 9 weeks after COVID19 illness, which was unrecognized for 3 months due to negative results
from an extensive neurological workup for myelitis, which led to

diagnostic uncertainty. This case highlights the need for physician vig
ilance in recognizing post-COVID-19 myelitis even months after initial
infection.
2. Case report
A 65-year-old woman with a history of borderline diabetes and
obesity (BMI 45.6) was referred to the neuroimmunology clinic to
evaluate idiopathic magnetic resonance imaging (MRI) negative TM.
In early April 2020, the patient became sick with symptoms con
cerning for COVID-19 illness. She had chills, headache, cough, shortness
of breath, fever, anorexia, and taste loss. She was prescribed prednisone
and antibiotics for one week and was recommended by her primary care
physician to self-quarantine. She was advised to go to the emergency
department (ED) for care after her symptoms worsened. SARS-CoV-2
testing was not done at that time. The patient made a full recovery
after 2 weeks and did not require hospitalization.
The patient remained in good health until June 12, 2020, when she
started having numbness in her feet that gradually ascended to her
trunk. Simultaneously, she noticed strange vibrations inside her body
upon neck flexion (Lhermitte’s phenomena). She had an imbalance and
weakness in her legs that led to falls. The patient also reported bladder
(urinary incontinence) and bowel dysfunction (constipation) and saddle
anesthesia. She had a televideo-visit with a neurologist on July 15, 2020
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and she was recommended to seek an urgent ED visit to evaluate
myelopathy. The patient presented to the ED the same day, and the
Neurology Department was consulted.
Neurologists noted upon examination that the patient had normal
upper and lower extremity strength with diffusely brisk reflexes and
positive Hoffman’s sign bilaterally. She had a sensory level at T10 with
diminished pinprick sensation. Temperature sensation was normal with
loss of vibratory sensation and impaired proprioception distally at her
toes. The patient had a wide-based cautious gait with a positive Rom
berg’s sign. She was admitted to the observation unit for 24 h. The pa
tient had magnetic resonance imaging (MRI) of the cervical, thoracic,
and lumbar spine (1.5 tesla) with and without contrast (Figure A–D),
which did not reveal any cord signal abnormality or evidence of
compressive myelopathy. No abnormal intramedullary or lep
tomeningeal enhancement was present within the spine. A SARS-CoV-2
nasopharyngeal PCR test done at this time was negative. Myeloneur
opathy laboratory results such as copper, B12, zinc, and lead levels were
checked and were within the reference range. Autoimmune laboratory
tests were mostly negative except for positive antinuclear antibodies
(1:320 speckled), rheumatoid factor 45 IU/mLL (<14IU/mL), and car
diolipin antibody IgM 14.1 MP L (<12.5 MP L). The patient had no
clinical features of rheumatoid arthritis. Infectious testing for Lyme
disease, syphilis, HIV, and HTLV I/II were all negative (supplementary
table). Given negative neuroimaging, outpatient neurology follow-up
and electromyography (EMG) was recommended to evaluate periph
eral nervous system diseases. She tested negative for serum aquaporin-4
IgG and MOG-IgG (myelin oligodendrocyte glycoprotein) antibodies.
The serum paraneoplastic panel assessed at the Mayo clinic and serum
angiotensin converting enzyme levels were normal.
The patient reported no family history of cancer, and computed to
mography (CT) imaging of the abdomen and pelvis was done to assess
possible malignancy, which was negative.Shortly after discharge from
the hospital, the patient started using a cane. Brain MRI (1.5 tesla)
completed 5 days after her discharge from the hospital showed a small
lacunar infarct in the right lateral pontine region (Fig. 1 E), which did
not explain her worsening symptoms. Spinal fluid analysis was recom
mended, but the patient elected not to undergo this procedure per
clinical documentation.
The patient presented to the ED again 6 days after her first hospi
talization for lower extremity pain, swelling, and progressive motor
weakness. On neurological examination during this visit, she was noted
to have 4/5 weakness with the right lower extremity hip flexion; the rest
of the examination was stable. She had a repeat SARS-CoV-2 nasopha
ryngeal PCR test, which was negative. In the ED, the patient had presyncope (dizziness), tachycardia, chest pain, and acute onset shortness
of breath. High-sensitivity troponin (790 ng/L, reference < 19 ng/L) and
D-dimer (19.22, reference<0.60 ug/mL FEU) levels were elevated. CT of
the chest with pulmonary embolism protocol revealed multiple bilateral
pulmonary emboli with right ventricular strain. CT chest did not reveal
mediastinal or hilar lymphadenopathy to suggest sarcoidosis. Lower
extremity venous doppler showed right totally occluding acute deep
vein thrombosis of the popliteal vein, soleal vein, and peroneal vein, and
left partially occluding acute deep vein thrombosis of the soleal vein.
The patient received catheter-directed, low-dose fibrinolysis via the
EKOS catheter for submassive pulmonary embolism and was later star
ted on intravenous heparin. The patient was admitted to the medical
intensive care unit for 2 days and transferred to the stepdown unit,
where she was observed for an additional 2 days. Her shortness of breath
and chest pain improved, and she was discharged home on apixaban 5
mg twice a day. Her pulmonary embolism was thought to have been
provoked by limited mobility. After discharge from the hospital, the
patient started using a walker. She had an outpatient EMG study done 11
days after discharge from her second hospitalization, which did not
indicate peripheral nerve disorders suchneuropathy or myopathy (sup
plementary table). The lumbar puncture was on hold because the patient
was on anticoagulation therapy. She was prescribed prednisone 60 mg

daily for 5 days, followed by a slow taper over one month with no
improvement in her symptoms. The patient received outpatient physical
therapy but made no progress. The patient then presented to an outside
hospital where she had a repeat MRI of the cervical and thoracic spine,
which was again reported as normal (we do not have access to the im
aging). She was discharged to inpatient rehabilitation, where the pa
tient’s condition continued to decline and she became wheelchair-bound
by September.
In mid-October 2020, the patient was seen in the neuroimmunology
clinic for idiopathic MRI-negative TM. On neurological examination, she
showed increased tone in her lower extremities and was paraplegic with
3/5 strength on knee extension. Upper extremity proximal strength was
normal 5/5 with deltoid, triceps, and biceps muscles. However, distally,
she had mild weakness 4/5 with finger extension, flexion, and abduc
tion. She had pathologically brisk reflexes in the upper and lower ex
tremities, with positive Hoffman’s sign, finger flexors signs bilaterally,
and non-sustained clonus at the ankles. Plantar responses were equiv
ocal. She had diminished sensation to light touch and pinprick up to the
groin, reduced vibratory sensation to 3 s up to knees with absent posi
tion sense distally in her toes. She manifested features of complete
myelitis. SARS-CoV-2 IgG and mycoplasma IgG antibody tests both were
positive.
The patient had repeat MRI of brain, cervical, thoracic, and lumbar
spine with and without contrast done on 3 Tesla machines. Brain MRI
showed high T2 signal intensity on fluid attenuated inverted recovery
sequence (FLAIR) involving the bilateral cortical spinal tracts affecting
the posterior limbs of internal capsules extending to the cerebral pe
duncles and faintly extending to the pons without associated enhance
ment (Figure F–G). MRI of the cervical spine revealed multifocal signal
abnormality present on sagittal FLAIR images of the cervical cord, from
skull base to C2-C3, C3-C4, and C5-C6. There was no abnormal intra
medullary or leptomeningeal enhancement. (Figure H–J). There was no
evidence for edema, expansion, or volume loss within the cervical. MRI
of thoracic spine was normal.
Given the lack of abnormal enhancement and restricted diffusion, a
demyelinating process was not suspected. Given progressive clinical
worsening and abnormal neuroimaging findings, inpatient admission to
neurology service was recommended to expedite the lumbar puncture
and treatment. The patient underwent lumbar puncture after apixaban
was withheld for 48 h (medication was safely resumed 24 h after lumbar
puncture). The cerebrospinal fluid (CSF) analysis showed mild pleocy
tosis with 20 white blood cells count (20/mm3) (predominantly
lymphocyte 91 %), elevated red blood cells (10/mm3), elevated serum
protein (81.6 g/dl), and normal CSF glucose (58 mg/dl).
Extensive CSF viral PCR studies for cytomegalovirus, varicella zoster,
Epstein-Barr, herpes simplex, human herpesvirus-6, and enterovirus
were all negative. CSF Gram stain and cultures were also negative. CSF
venereal disease research laboratory (VDRL), cytology, mycoplasma
PCR, and HTLV-1 and 2 antibody tests were negative. CSF was positive
for the West Nile IgG antibody but West Nile IgM antibody was negative.
CSF paraneoplastic panel (Mayo clinic), serum NMDA-receptor anti
body, and ILG1-antibody tests were also negative. SARS-CoV-2 IgM and
repeat IgG tests were both reactive. Mycoplasma IgM and repeat IgG
tests were both negative at this time (supplementary table).
The patient received high dose pulse intravenous steroid, methyl
prednisolone 1 g for 5 days, with no improvement in her symptoms. She
then received 5 rounds of plasma exchange (PLEX) every other day and
reported subjective improvement in her sensory symptoms only. She had
a repeat EMG during hospitalization, which did not show any peripheral
etiology for her symptoms (supplementary table). Follow-up MRI of the
brain and cervical spine with and without contrast after PLEX was un
changed to slightly improved due to differences in MR magnets and
motion suggest stability (Figure, K–M). MRI thoracic and lumbar spine
remained normal.
The patient was discharged to inpatient rehabilitation with outpa
tient neurology follow-up. Per the last conversation with the patient
2
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Fig. 1. Spinal MRI-evolution of myelitis and brain corticospinal tract changes. Saggital T2- weighted initial MRI cervical, thoracic and lumbar spine (A-D).
Initial Brain MRI DWI showing diffusion restriction in the right lateral pontine region (red arrow, E). Repeat brain MRI axial-FLAIR showing T2-signal changes
involving the bilateral cortical spinal tracts affecting the posterior limbs of internal capsules extending to the cerebral peduncles (red arrows, F) and pons (red arrows,
G). Repeat MRI cervical spine show multifocal T2-signal changes in the cervical cord (C2-C6) on sagittal-STIR (red arrows, I) without associated enhancement (J)
confirmed on the axial T2-weighted sequence (red arrows, H). Post-treatment repeat MRI C shows faint patchy T2 signal changes on sagittal FLAIR (red arrows, L)
confirmed on axial T2-weighted sequence (red arrows, K). Post treatment repeat brain MRI axial FLAIR is unchanged (M). DWI = diffusion weighted images, FLAIR =
fluid-attenuated inversion recovery, STIR = short TI inversion recovery.
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over the phone, she reported that she could move her feet and kick her
legs further out, which she could not do before treatment. She can now
slowly pull her legs back and she can stand with bilateral assistance for
about one minute. The patient believes that she is very slowly making
progress.

tracts could raise a concern for rapidly progressive motor neuron dis
ease, such as amyotrophic lateral sclerosis. But our patient’s history of
ascending sensory paresthesia followed by motor weakness and negative
EMG on 2 occasions does not support the diagnosis of motor neuron
disease.
A similar brain abnormality was reported in another COVID-19 pa
tient, where bilateral corticospinal tract lesions in internal capsules
extending to the cerebral peduncles and pons associated with evidence
of longitudinally extensive transverse myelitis were seen on spinal
neuroimaging. [14] Clinically, this patient behaved differently
compared to our patient, as she manifested mild encephalopathy, acute
onset of TM 2 weeks after COVID-19 illness, and had a good response to
immunotherapy (PLEX). [14] Perhaps one might argue that early initi
ation of immunotherapy could have changed our patient’s clinical
outcome. SARS-CoV-1 studies have shown that viral replication can
delay the self-reactive T-cell suppression, leading to central nervous
system neuroinflammation, demyelination, and axonal damage [15,16].
Our patient’s case highlights several interesting aspects of post
− COVID-19 myelitis, including late manifestation of myelitis months
after the viral illness, rapidly progressive disease, and MRI-negative
spinal imaging at the onset of disease that led to diagnostic uncer
tainty, which dissuaded early initiation of immunotherapy. This atypical
presentation of myelitis raises concern for a slow or delayed immunemediated pathogenesis that happened in response to the SARS-COV-2
virus or its antibodies.

3. Discussion
Our patient presented with late-onset partial myelitis that progressed
to complete myelitis over 3 months, which was preceded by the COVID19 illness 9 weeks before her neurological manifestation. Extensive in
fectious, inflammatory autoimmune, neoplastic, and paraneoplastic in
vestigations were negative. CSF was positive for West Nile IgG antibody;
however, the patient’s clinical presentation and EMG results were not
suggestive of lower motor neuron illness seen in West Nile virus infec
tion. This could be due to SARS-CoV-2 antibody cross-reactivity with the
West Nile Virus, also seen in antibody-induced by other flavivirus in
fections (e.g. Dengue virus, St. Louis encephalitis virus).
Although she had positive initial serum mycoplasma IgG test, the
repeat antibody tests (IgM and IgG) and a CSF mycoplasma PCR test
were negative, which suggests an initial false positive result. This elu
cidates a possible post-infectious or immune-mediated myelitis after
COVID-19 illness. About 30 %–60 % of idiopathic TM cases are preceded
by a gastrointestinal, respiratory, or systemic disease. The onset of in
fectious myelitis symptoms is typically hours to days, but can be months
to years after infection, as seen with human T cell lymphotropic virus-1
(HTLV-1) associated myelopathy. [9] Several mechanisms are involved
in TM’s microbial pathogenesis: bystander effects, molecular mimicry,
immune complex deposition, and microbial super-antigen mediated
inflammation and humoral response [10].
In bystander effects, the pathogen directly invades the CSF or causes
indirect damage through an immune-mediated process, as can happen in
para-infectious TM. Molecular mimicry is when there is antigenic sim
ilarity between pathogen antigens and the human tissue. [10] Molecular
mimicry and immune complex deposition have been elucidated as one of
the immunopathogenic processes involved in Mycoplasma pneumoniae
post-infectious TM. Another interesting mechanism is the activation of
lymphocytes by microbial superantigens that can initiate immunopa
thogenesis and lead to autoimmune diseases. [11] This has been re
ported in association with COVID-19 in a 15-year old male patient who
was diagnosed with anti-MOG IgG associated bilateral optic neuritis a
few weeks after COVID-19 illness [12]. The interesting feature in that
case was the patient’s normal MRI scans (1.5 tesla magnet) on at least 2
occasions, which was a misleading factor that delayed immunotherapy.
MRI-negative myelitis is reported to be associated with anti-MOG au
toantibodies [13], and our patient tested negative for the MOG-IgG
antibody. Her repeat MRI scans performed on 3-tesla magnet showed
multifocal myelitis affecting the cervical cord. High T2 signal intensity
involving the bilateral cortical spinal tracts affecting the posterior limbs
of internal capsules extending to the cerebral peduncles, and faintly
extending to the pons without associated enhancement. These results
raise concern for possible Wallerian degeneration, as the patient did not
manifest any features of encephalitis or cranial neuropathies from the
brainstem involvement throughout her disease course. We speculate
that these results indicate an intense axonal degeneration without
demyelination that can be seen in severe viral-induced pathogenesis and
therefore was not seen on the MRI scan earlier in our patient’s disease
course. Pathological processes that extensively affect the corticospinal
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[5] J. Sotoca, Y. Rodríguez-Álvarez, COVID-19-associated acute necrotizing myelitis,
Neurol. Neuroimmunol. Neuroinflamm. 7 (June 5) (2020) e803, https://doi.org/
10.1212/NXI.0000000000000803. Print 2020 Sep.
[6] R. AlKetbi, D. AlNuaimi, M. AlMulla, N. AlTalai, M. Samir, N. Kumar, U. AlBastaki,
Acute myelitis as a neurological complication of Covid-19: a case report and MRI
findings, Radiol. Case Rep. 15 (June 9) (2020) 1591–1595, https://doi.org/
10.1016/j.radcr.2020.06.001.
[7] Y. Rodríguez, M. Rojas, Y. Pacheco, Y. Acosta-Ampudia, C. Ramírez-Santana, D.
M. Monsalve, M.E. Gershwin, J.M. Anaya, Guillain Barre syndrome, transverse
myelitis and infectious diseases, Cell. Mol. Immunol. 15 (June 6) (2018) 547–562,
https://doi.org/10.1038/cmi.2017.142. Epub 2018 Jan 29.

5

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on February 25, 2021.
For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

